symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
PKBO,0.115,-0.10758,25410,2518937,0,0.077-15.0,0.005,"Peak Bio, Inc.",USD,0001834645,,,NASDAQ Capital Market,NASDAQ,Biotechnology,https://peak-bio.com,"Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.","Dr. Stephen  LaMond M.B.A., Pharm.D., PharmD MBA",Healthcare,US,21,650-549-9103,3350 W Bayshore Rd.,Palo Alto,CA,94303,,0,https://financialmodelingprep.com/image-stock/PKBO.png,2021-03-15,True,False,True,False,False
